TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis

被引:43
作者
Cruz-Muñoz, W
Kim, I
Khokha, R
机构
[1] Dept Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
TIMP-3; host stroma; B16F10; teratoma; angiogenesis;
D O I
10.1038/sj.onc.1209104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor cells, stromal cell compartment and the extracellular matrix (ECM) together generate a multifaceted tumor microenvironment. Matrix metalloproteinases and their tissue inhibitors (TIMPs) provide a means for tumor-stromal interaction during tumorigenesis. Among TIMPs, TIMP-3 is uniquely localized to the ECM and is frequently silenced in human cancers. Here, we asked whether the absence of TIMP-3 in the tumor cell or the host affects the process of tumorigenesis. Timp-3(-/-) ES-cell clones were generated and used to develop teratomas in nude mice. Timp-3(-/-) teratomas showed similar tumor take, growth, and angiogenesis compared to timp-3(-/-) teratomas. To study the effect of TIMP-3 ablation in the host stroma, we measured the growth kinetics of subcutaneous B16F10 melanomas in timp-3(-/-) and wildtype littermates. Tumors grew significantly faster in timp3(-/-) than in wild-type mice and their CD31 content was significantly higher indicating increased angiogenesis. Augmented angiogenesis in timp-3(-/-) mice was directly tested using Matrigel plug and Gelfoam assays. In response to FGF-2, timp-3(-/-) endothelial cells invaded more efficiently, leading to enhanced formation of functional blood vessels. Thus, TIMP-3 deficiency in the host, but not in the tumor per se, leads to enhanced tumor growth and angiogenesis. TIMP-3 located within the tumor microenvironment inhibits tumorigenesis.
引用
收藏
页码:650 / 655
页数:6
相关论文
共 46 条
[1]  
AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817
[2]   A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth [J].
AnandApte, B ;
Bao, L ;
Smith, R ;
Iwata, K ;
Olsen, BR ;
Zetter, B ;
Apte, SS .
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1996, 74 (06) :853-862
[3]   Gene trapping identifies inhibitors of oncogenic transformation -: The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I α2 (COL1A2) are epidermal growth factor-regulated growth repressors [J].
Andreú, T ;
Beckers, T ;
Thoenes, E ;
Hilgard, P ;
von Melchner, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (22) :13848-13854
[4]  
Bachman KE, 1999, CANCER RES, V59, P798
[5]   Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3 [J].
Bian, JH ;
Wang, YL ;
Smith, MR ;
Kim, H ;
Jacobs, C ;
Jackman, J ;
Kung, HF ;
Colburn, NH ;
Sun, Y .
CARCINOGENESIS, 1996, 17 (09) :1805-1811
[6]  
BOOKS PC, 1996, CELL, V85, P683
[7]  
Boulay A, 2001, CANCER RES, V61, P2189
[8]   Membrane-type matrix metalloproteinases in human dermal microvascular endothelial cells: Expression and morphogenetic correlation [J].
Chan, VT ;
Zhang, DN ;
Nagaravapu, U ;
Hultquist, K ;
Romero, LI ;
Herron, GS .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 111 (06) :1153-1159
[9]   Cancer therapy - Matrix metalloproteinase inhibitors and cancer: Trials and tribulations [J].
Coussens, LM ;
Fingleton, B ;
Matrisian, LM .
SCIENCE, 2002, 295 (5564) :2387-2392
[10]   Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer [J].
DeClerck, YA .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (10) :1258-1268